Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nuala Moran

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Nature Biotechnology|April 12, 2012
Biotech innovators jump on biosimilars bandwagonNuala Moran
Nature Biotechnology|July 10, 2009
Sanofi Aventis grooms its ranks for biotech partneringNuala Moran
Nature Biotechnology|September 12, 2012
First gene therapy nears landmark European market authorizationNuala Moran
Scientific American|July 13, 2005
Tough cell to investors. Venture capitalists are wary of investing in companies in which risks in the science may not be rewarded by a health revenue streamNuala Moran
Nature Biotechnology|February 9, 2006
Nanomedicine lacks recognition in EuropeNuala Moran
Nature Biotechnology|May 10, 2013
No-fee university licenses spur biotech partnershipsNuala Moran
Nature Biotechnology|February 9, 2013
Startups, inventors cheer European unified patentNuala Moran
Nature Biotechnology|February 9, 2013
Brüstle patent holds up in GermanyNuala Moran
Nature Biotechnology|October 12, 2018
FDA approves Galafold, a triumph for AmicusNuala Moran
Nature Biotechnology|September 12, 2007
BioPolis report paints fractured picture of EU biotechNuala Moran
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Nature Biotechnology|April 12, 2012
Biotech innovators jump on biosimilars bandwagonNuala Moran
Nature Biotechnology|July 10, 2009
Sanofi Aventis grooms its ranks for biotech partneringNuala Moran
Nature Biotechnology|September 12, 2012
First gene therapy nears landmark European market authorizationNuala Moran
Scientific American|July 13, 2005
Tough cell to investors. Venture capitalists are wary of investing in companies in which risks in the science may not be rewarded by a health revenue streamNuala Moran
Nature Biotechnology|February 9, 2006
Nanomedicine lacks recognition in EuropeNuala Moran
Nature Biotechnology|May 10, 2013
No-fee university licenses spur biotech partnershipsNuala Moran
Nature Biotechnology|February 9, 2013
Startups, inventors cheer European unified patentNuala Moran
Nature Biotechnology|February 9, 2013
Brüstle patent holds up in GermanyNuala Moran
Nature Biotechnology|October 12, 2018
FDA approves Galafold, a triumph for AmicusNuala Moran
Nature Biotechnology|September 12, 2007
BioPolis report paints fractured picture of EU biotechNuala Moran
Pageof 5